Selectivity assessment of kinase inhibitors: Strategies and challenges

Current Opinion in Molecular Therapeutics

Volumn 7, Issue 3, 2005, Pages 251-255

  Luo, Yan ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

Chemical genomics; Chemical proteomics; Kinase selectivity; Kinome profiling; Multiplex; Phosphorylation array

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ADENOSINE TRIPHOSPHATE; BACTERIOPHAGE DNA; BISINDOLYLMALEIMIDE; CYCLIN DEPENDENT KINASE INHIBITOR; ERLOTINIB; GEFITINIB; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; GW 400426; IMATINIB; PAULLONE DERIVATIVE; PHA 539136; PHOSPHOTRANSFERASE; PHOSPHOTRANSFERASE INHIBITOR; TWS 119; UNCLASSIFIED DRUG;

COMPETITIVE INHIBITION; DRUG DESIGN; DRUG INDUSTRY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; ENZYME INHIBITION; GENE TECHNOLOGY; PHAGE DISPLAY; PROTEIN MICROARRAY; PROTEIN PHOSPHORYLATION; REVIEW;

ANIMALS; BINDING SITES; DRUG DESIGN; HUMANS; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 20344366516     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (26)

1. Capdeville R, Buchdunger E, Zimmermann J, Matter A: Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov (2002) 1(7):493-502.
2. DeMatteo RP: The GIST of targeted cancer therapy: A tumor (gastrointestinal stromal tumor), a mutated gene (c-kit), and a molecular inhibitor (STI571). Ann Surg Oncol (2002) 9(9):831-839.
3. Davies SP, Reddy H, Caivano M, Cohen P: Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J (2000) 351(1):95-105.
4. Hanks SK, Hunter T: Protein kinases 6. The eukaryotic protein kinase superfamily: Kinase (catalytic) domain structure and classification. FASEB J (1995) 9(8):576-596.
5. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S: The protein kinase complement of the human genome. Science (2002) 298(5600):1912-1934.
6. Luo Y, Shoemaker AR, Liu X, Woods KW, Thomas SA, de Jong R, Han EK, Li T, Stoll VS, Powlas JA, Oleksijew A et al: Potent and selective inhibitors of Akt kinases slow the progression of tumors in vivo. Mol Cancer Ther (2005): manuscript submitted.
7. Vieth M, Higgs RE, Robertson DH, Shapiro M, Gragg EA, Hemmerle H: Kinomics-structural biology and chemogenomics of kinase inhibitors and targets. Biochim Biophys Acta (2004) 1697(1-2):243-257.
8. Fabian MA, Biggs WH, Treiber DK, Atteridge CE, Azimioara MD, Benedetti MG, Carter TA, Ciceri P, Edeen PT, Floyd M, Ford JM et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol (2005) 23(3):329-336.
9. Becker F, Murthi K, Smith C, Come J, Costa-Roldán N, Kaufmann C, Hanke U, Degenhart C, Baumann S, Wallner W, Huber A et al. A three-hybrid approach to scanning the proteome for targets of small molecule kinase inhibitors. Chem Biol (2004) 11(2):211-223.
10. Pelech S: Tracking cell signaling protein expression and phosphorylation by innovative proteomic solutions. Curr Pharm Biotechnol (2004) 5(1):69-77.
11. Lorenz P, Ruschpler P, Koczan D, Stiehl P, Thiesen HJ: From transcriptome to proteome: Differentially expressed proteins identified in synovial tissue of patients suffering from rheumatoid arthritis and osteoarthritis by an initial screen with a panel of 791 antibodies. Proteomics (2003) 3(6):991-1002.
12. Yamagiwa Y, Marienfeld C, Meng F, Holcik M, Patel T: Translational regulation of X-linked inhibitor of apoptosis protein by interleukin-6: A novel mechanism of tumor cell survival. Cancer Res (2004) 64(4):1293-1298.
13. Chan SM, Ermann J, Su L, Fathman CG, Utz PJ: Protein microarrays for multiplex analysis of signal transduction pathways. Nat Med (2004) 10(12):1390-1396.
14. Godl K, Wissing J, Kurtenbach A, Habenberger P, Blencke S, Gutbrod H, Salassidis K, Stein-Gerlach M, Missio A, Cotten M, Daub H: An efficient proteomics method to identify the cellular targets of protein kinase inhibitors. Proc Natl Acad Sci USA (2003) 100(26):15434-15439.
15. Ueda K, Kosako H, Fukui Y, Hattori S: Proteomic identification of Bcl2-associated athanogene 2 as a novel MAPK-activated protein kinase 2 substrate. J Biol Chem (2004) 279(40):41815-41821.
16. Rush J, Moritz A, Lee KA, Guo A, Goss VL, Spek EJ, Zhang H, Zha XM, Polakiewicz RD, Comb MJ: Immunoaffinity profiling of tyrosine phosphorylation in cancer cells. Nat Biotechnol (2005) 23(1):94-101.
17. Daub H, Godl K, Brehmer D, Klebl B, Müller G: Evaluation of kinase inhibitor selectivity by chemical proteomics. Assay Drug Dev Technol (2004) 2(2):215-224.
18. Knockaert M, Gray N, Damiens E, Chang YT, Grellier P, Grant K, Fergusson D, Mottram J, Soete M, Dubremetz JF, Le Roch K et al: Intracellular targets of cyclin-dependent kinase inhibitors: Identification by affinity chromatography using immobilised inhibitors. Chem Biol (2000) 7(6):411-422.
19. Knockaert M, Wieking K, Schmitt S, Leost M, Grant- Karen M, Mottram JC, Kunick C, Meijer L: Intracellular targets of paullones. Identification following affinity purification on immobilized inhibitor. J Biol Chem (2002) 277(28):25493-25501.
20. Brehmer D, Godl K, Zech B, Wissing J, Daub H: Proteome-wide identification of cellular targets affected by bisindolylmaleimidetype protein kinase C inhibitors. Mol Cell Proteomics (2004) 3(5):490-500.
21. Brehmer D, Greff Z, Godl K, Blencke S, Kurtenbach A, Weber M, Müller S, Klebl B, Cotten M, Kéri G, Wissing J, Daub H: Cellular targets of gefitinib. Cancer Res (2005) 65(2):379-382.
22. Wan Y, Hur W, Cho CY, Liu Y, Adrian FJ, Lozach O, Bach S, Mayer T, Fabbro D, Meijer L, Gray NS: Synthesis and target identification of hymenialdisine analogs. Chem Biol (2004) 11(2):247-259.
23. Lolli G, Thaler F, Valsasina B, Roletto, F, Knapp S, Uggeri M, Bachi A, Matafora V, Storici P, Stewart A, Kalisz HM, Isacchi A: Inhibitor affinity chromatography: Profiling the specific reactivity of the proteome with immobilized molecules. Proteomics (2003) 3(7):1287-1298.
24. Ding S, Wu TYH, Brinker A, Peters EC, Hur W, Gray NS, Schultz PG: Synthetic small molecules that control stem cell fate. Proc Natl Acad Sci USA (2003) 100(13):7632-7637.
25. Serenex. World Wide Web Site (2005). www.serenex.com.
26. Kung C, Kenski DM, Dickerson SH, Howson RW, Kuyper LF, Madhani HD, Shokat KM: Chemical genomic profiling to identify intracellular targets of a multiplex kinase inhibitor. Proc, Natl Acad Sci USA (2005) 102(10):3587-3592.